Sanofi and Sobi's hemophilia drug meets phase III primary endpoint
![Photo: John Ambrose / Sobi / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13809045.ece/ALTERNATES/schema-16_9/doc7k1mnjfmdqb6g4lx2i8.jpg)
Sanofi and Swedish Orphan Biovitrum, commonly known as Sobi, have presented positive top line results from a phase III trial with efanesoctocog, a hemophilia A treatment candidate, as reported in a press release on Wednesday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.